Small molecule FPR/NOX2 agonists

Development of proprietary unique nM potent agonist of FPR/NOX2

for treatment of autoimmunity, inflammation and infections

Welcome to Pronoxis

ProNoxis focuses on the preclinical discovery of small-molecule drugs to treat chronic inflammation, autoimmunity and infections.

ProNoxis AB was founded in 2009 by LU Bioscience AB (LUBio), Karolinska Development AB, and Redoxis AB, as a Redoxis spin-off focusing on developing anti-inflammatory therapeutics targeting activation of the NADPH oxidase complex (NOX2).

Since 2024, Pronoxis AB is owned by its founder and CEO Dr. Peter Olofsson-Sahl